"As President Trump weighs marijuana rescheduling in the coming weeks, the DEA's track record reveals years of mismanagement, empty promises,…
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing…
Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site…
Black Book Research Flash Survey of 126 Healthcare Investors Pinpoints Largely Untapped, High-Conviction Markets for Startups, Scaleups, and Strategic Expansion…
Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287,…
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive…
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial…
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi®…
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight…
The untold truth? Rescheduling may not save the cannabis industry-it could divide it.Past IRS 280E tax liabilities won't vanish-some companies…